Ranivisio 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
N/0013 
Minor change in labelling or package leaflet not 
12/10/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0011 
B.II.g.5.c - Implementation of changes foreseen in 
05/10/2023 
n/a 
an approved change management protocol - For a 
biological/immunological medicinal product 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
II/0006 
B.II.b.2.b - Change to importer, batch release 
05/10/2023 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place for a biol/immunol 
product and any of the test methods at the site is a 
biol/immunol method 
II/0005 
B.I.a.1.j - Change in the manufacturer of AS or of a 
05/10/2023 
n/a 
starting material/reagent/intermediate for AS -  
Replacement or addition of a site where batch 
control/testing takes place and any of the test 
method at the site is a biol/immunol method 
IAIN/0012 
B.II.b.1.a - Replacement or addition of a 
11/09/2023 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0009 
B.IV.1.a.1 - Change of a measuring or administration 
31/08/2023 
22/09/2023 
SmPC and PL 
device - Addition or replacement of a device which is 
not an integrated part of the primary packaging - 
Device with CE marking 
II/0008 
B.I.a.4.e - Change to in-process tests or limits 
31/08/2023 
n/a 
applied during the manufacture of the AS - Deletion 
of an in-process test which may have a significant 
effect on the overall quality of the AS 
IB/0010 
B.I.b.2.e - Change in test procedure for AS or 
28/07/2023 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
Page 2/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
or addition) for the AS or a starting 
material/intermediate 
PSUSA/2609/
Periodic Safety Update EU Single assessment - 
12/05/2023 
n/a 
PRAC Recommendation - maintenance 
202210 
ranibizumab 
IB/0004 
B.I.b.2.a - Change in test procedure for AS or 
20/04/2023 
n/a 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IB/0003 
C.I.2.a - Change in the SPC, Labelling or PL of a 
24/01/2023 
22/09/2023 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0001 
B.II.b.2.c.1 - Change to importer, batch release 
04/10/2022 
22/09/2023 
SmPC, Annex 
arrangements and quality control testing of the FP - 
II and PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
Page 3/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
